Jenna Ellis
Manager
专长:
Jenna is a Manager on the Value & Evidence team at EVERSANA with experience conducting indirect treatment comparisons.
Since joining the team in 2022, Jenna has been involved in the development and execution of several indirect treatment comparisons including methods such as network meta-analysis, penalized likelihood network meta-analysis, multilevel network meta-regression, matching-adjusted indirect comparison, and simulated treatment comparison.
Jenna is well-versed in evidence synthesis. Prior to joining EVERSANA, she was part of a research team responsible for one of the largest systematic reviews in the Cochrane library and has also conducted meta-epidemiological research on the quality of trials used in evidence synthesis.
Jenna holds an MSc in Epidemiology specializing in Biostatistics from Queen’s University.
Articles by Jenna Ellis
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have been demonstrated for many 1L mCRPC treatments, including novel agents such as talazoparib plus enzalutamide. However, due to the […]
Filling in the Gaps: Predicting Treatment Effects From Surrogate Endpoints
Over the past 15 years, the treatment landscape for first-line metastatic castration-resistant prostate cancer (mCRPC) has undergone significant changes, marked by the approval and investigation of several new therapies. With multiple pharmacological treatments available for first-line mCRPC, network meta-analyses (NMAs) can serve as a valuable resource for evaluating clinical effectiveness that reflects current and local […]